Trial Profile
Montelukast as a controller of atopic syndrome.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 May 2022
Price :
$35
*
At a glance
- Drugs Montelukast (Primary)
- Indications Allergic asthma; Allergic conjunctivitis; Allergic rhinitis; Atopic dermatitis; Hypersensitivity; Urticaria
- Focus Therapeutic Use
- Acronyms MONTAS
- 27 Nov 2007 New trial record.